Skip to main content
Terug
IVBXF logo

Innovent Biologics, Inc.

Datakwaliteit: 100%
IVBXF
OTC Healthcare Biotechnology
€ 9,75
▼ € 1,02 (-9,47%)
Marktkapitalisatie: 16,78B
Dagbereik
€ 9,75 € 11,36
52-Weeksbereik
€ 5,00 € 15,12
Volume
200
50D / 200D Gem.
€ 10,76 / € 11,34
Vorige Slotkoers
€ 10,77

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -177,3 0,4
P/B 1,3 2,9
ROE % -0,7 3,7
Net Margin % -1,0 3,9
Rev Growth 5Y % 25,1 10,0
D/E 0,2 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 5,70
€ 3,93 – € 9,22
41 B 1
FY2028 € 5,68
€ 3,92 – € 9,19
32 B 1
FY2027 € 2,53
€ 1,74 – € 4,09
22 B 1

Belangrijkste Punten

Revenue grew 25,12% annually over 5 years — strong growth
Debt/Equity of 0,22 — conservative balance sheet
Negative free cash flow of -418,39M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 26,70%

Groei

Revenue Growth (5Y)
25,12%
Revenue (1Y)51,82%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-0,74%
ROIC-3,55%
Net Margin-1,00%
Op. Margin-8,02%

Veiligheid

Debt / Equity
0,22
Current Ratio2,35
Interest Coverage-11,17

Waardering

P/E Ratio
-177,30
P/B Ratio1,28
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 51,82% Revenue Growth (3Y) 43,80%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 25,12% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9,42B Net Income (TTM) -94,63M
ROE -0,74% ROA -0,44%
Gross Margin 83,97% Operating Margin -8,02%
Net Margin -1,00% Free Cash Flow (TTM) -418,39M
ROIC -3,55% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,22 Current Ratio 2,35
Interest Coverage -11,17 Dividend Yield 0,00%
Valuation
P/E Ratio -177,30 P/B Ratio 1,28
P/S Ratio 1,78 PEG Ratio 6,00
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 16,78B Enterprise Value 12,10B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 9,42B 6,21B 4,56B 4,27B 3,84B
Net Income -94,63M -1,03B -2,18B -2,73B -998,42M
EPS (Diluted) -0,06 -0,66 -1,46 -1,88 -0,74
Gross Profit 7,91B 4,40B 3,63B 3,70B 3,46B
Operating Income -755,87M -1,68B -3,12B -2,70B -557,19M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 21,60B 20,63B 17,59B 16,24B 11,83B
Total Liabilities 8,48B 8,10B 6,86B 5,91B 3,06B
Shareholders' Equity 13,12B 12,53B 10,73B 10,33B 8,78B
Total Debt 2,83B 3,62B 3,23B 2,50B 1,21B
Cash & Equivalents 7,51B 10,05B 1,02B 1,36B 1,28B
Current Assets 10,27B 13,43B 11,51B 11,55B 9,47B
Current Liabilities 4,37B 4,48B 3,50B 3,05B 1,49B